A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

In 2021, the FDA ap­proved Bris­tol My­ers Squibb’s Breyanzi for some adult lym­phoma pa­tients, mak­ing it the third CAR-T ther­a­py to be­come com­mer­cial­ly avail­able.

The treat­ment was in­vent­ed at Seat­tle Chil­dren’s Hos­pi­tal, and the first clin­i­cal study was in pe­di­atric pa­tients. Mike Jensen, chief ther­a­peu­tics of­fi­cer at Seat­tle Chil­dren’s and the physi­cian-sci­en­tist be­hind Breyanzi, hoped that Bris­tol My­ers would seek ap­proval for chil­dren next.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER